UPDATE 3-Biogen sees gradual Spinraza launch, eyes mid-year EU approval
Jan 26 (Reuters) - Biogen Inc said on Thursday that the first U.S. patients have received its new drug for the leading genetic cause of death in infants and that it anticipates mid-year approval of... [Source]
Publication Date:Origin: reuters.com
Category: hotStocksNews
Topics: approval, mid-year, it anticipates, infants, death, cause, genetic, the leading, received, patients, first, that the, Biogen, (Reuters), launch, Spinraza, gradual, 3-Biogen, UPDATE
Source: http://feeds.reuters.com/~r/reuters/hotStocksNews/~3/Y7ChZANoqrI/biogen-results-idUSL4N1FG3HY